Graphical Abstract: We identified a novel population of CD4 tumour‐infiltrating lymphocytes (TILs) in BLCA, defined as the co‐expression of PD‐1 and CD200, which may help to explore the mechanisms of tumour progression and immunotherapy resistance. The gene discussed is PDCD1; the disease is neoplasm.